Cantor Fitzgerald Expects Reduced Earnings for Belite Bio

Belite Bio, Inc (NASDAQ:BLTE) – Research analysts at Cantor Fitzgerald lowered their FY2025 EPS estimates for shares of Belite Bio in a report released on Tuesday, March 18th. Cantor Fitzgerald analyst J. Kim now anticipates that the company will post earnings of ($1.36) per share for the year, down from their previous forecast of ($1.30). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Belite Bio’s current full-year earnings is ($1.17) per share.

Belite Bio (NASDAQ:BLTE) last announced its quarterly earnings data on Monday, March 17th. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02).

BLTE has been the subject of a number of other reports. HC Wainwright reaffirmed a “buy” rating and set a $100.00 price objective on shares of Belite Bio in a research note on Tuesday. Benchmark boosted their price target on shares of Belite Bio from $57.00 to $79.00 and gave the company a “buy” rating in a report on Tuesday, January 21st.

Belite Bio Stock Down 0.7 %

Shares of NASDAQ BLTE opened at $67.28 on Thursday. Belite Bio has a 12 month low of $31.01 and a 12 month high of $86.53. The company has a market cap of $2.14 billion, a price-to-earnings ratio of -60.61 and a beta of -1.54. The business has a fifty day simple moving average of $59.48 and a 200-day simple moving average of $60.84.

Institutional Trading of Belite Bio

Several institutional investors have recently made changes to their positions in BLTE. Bank of America Corp DE increased its position in Belite Bio by 36.4% in the 4th quarter. Bank of America Corp DE now owns 18,342 shares of the company’s stock worth $1,157,000 after purchasing an additional 4,891 shares during the last quarter. BNP Paribas Financial Markets acquired a new position in Belite Bio in the fourth quarter worth approximately $155,000. XTX Topco Ltd raised its position in Belite Bio by 30.9% during the fourth quarter. XTX Topco Ltd now owns 7,062 shares of the company’s stock valued at $446,000 after acquiring an additional 1,668 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Belite Bio by 130.3% in the fourth quarter. JPMorgan Chase & Co. now owns 14,636 shares of the company’s stock valued at $924,000 after acquiring an additional 8,280 shares during the last quarter. Finally, Advisors Preferred LLC acquired a new stake in Belite Bio in the fourth quarter valued at approximately $52,000. 0.53% of the stock is currently owned by institutional investors and hedge funds.

Belite Bio Company Profile

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.